The optimal use of PEG-asparaginase in relapsed ALL--lessons from the ALLR3 Clinical Trial.
Children's Cancer Group, Manchester Academic Health Sciences Centre, Institute of Cancer, University of Manchester, Manchester, UK.
A
A
Masurekar
Children's Cancer Group, Manchester Academic Health Sciences Centre, Institute of Cancer, University of Manchester, Manchester, UK.
C
C
Fong
Children's Cancer Group, Manchester Academic Health Sciences Centre, Institute of Cancer, University of Manchester, Manchester, UK.
A
A
Hussein
Department of Haematology-Oncology, SA Pathology at Women's and Children's Hospital and University of Adelaide, Adelaide, South Australia, Australia.
T
T
Revesz
1] Childrens Hospital, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands [2] Dutch 17 Childhood Oncology Group, The Hague, The Netherlands.
P M
PM
Hoogerbrugge
Centre for Statistics in Medicine, University of Oxford, Oxford, UK.
S
S
Love
Centre for Statistics in Medicine, University of Oxford, Oxford, UK.
C
C
Ciria
Children's Cancer Group, Manchester Academic Health Sciences Centre, Institute of Cancer, University of Manchester, Manchester, UK.
C
C
Parker
1] Children's Cancer Group, Manchester Academic Health Sciences Centre, Institute of Cancer, University of Manchester, Manchester, UK [2] Department of Paediatric Oncology, Tata Translational Cancer Research Centre, Kolkata, India.
S
S
Krishnan
1] Children's Cancer Group, Manchester Academic Health Sciences Centre, Institute of Cancer, University of Manchester, Manchester, UK [2] Department of Paediatric Oncology, Tata Translational Cancer Research Centre, Kolkata, India.
V
V
Saha
D000293:Adolescent; D001215:Asparaginase / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
D011092:Polyethylene Glycols; C042705:pegaspargase; D001215:Asparaginase